Xcout Intel
Immugenia competitors & alternatives
The 12 closest competitors and alternatives to Immugenia among biotechnology companies — ranked by similarity to what Immugenia actually does, not by market-cap band.
Subscribe to see Immugenia’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Immugenia
Immugenia Inc. is a preclinical-stage immuno-oncology company located in Sherbrooke, Quebec, Canada, developing next-generation CAR therapies by engineering hematopoietic stem cells to treat and prevent cancer relapses.
Immugenia at a glance
Immugenia is a biotechnology company headquartered in Canada. Its most recent funding round, Pre-Seed, closed in October 2022. Xcout tracks 3 named people at Immugenia, including Stéphane Gagné (Chief Executive Officer).
Immugenia leadership
- Stéphane GagnéChief Executive Officer
- Brigitte LemieuxMarketing Director
- Kathie BélandResearch Director
Immugenia funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Pre-Seed | Undisclosed | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Immugenia competitors
Ranked by semantic similarity — how close each company is to Immugenia by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
ImmuneBridge Inc. is a biotechnology company headquartered in San Francisco, California, that develops a hematopoietic stem cell (HSC) expansion and differentiation platform.
Similar biotechnology company
TATUM Bioscience is a biotechnology research company headquartered in Sherbrooke, Canada, pioneering nanofilament immunotherapy for cancer treatment. Their breakthrough technology is designed to boost tumor visibility and restore anti-tumor immune responses.
Similar biotechnology company
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Similar biotechnology company
Noile-Immune Biotech Inc. is a biotechnology company incorporated in 2015 and headquartered in Tokyo, Japan. The company specializes in the development of next-generation cancer immunotherapies, including advanced CAR-T cell technologies.
Similar biotechnology company
9Bio Therapeutics is a biotechnology company that combines biology, structural engineering, and artificial intelligence to pioneer next-generation biologics for advanced cancers. The company is headquartered in Quebec, Canada.
Similar biotechnology company
Cimeio Therapeutics is a privately held, applied gene editing, cellular, and immunotherapy company headquartered in Cambridge, Massachusetts. Founded in 2020, the company is dedicated to transforming hematopoietic stem cell transplantation and cellular therapies.
Similar biotechnology company
Pan Cancer T develops pioneering T-cell receptor (TCR-T) cell therapies designed to empower patients' immune systems to target and overcome solid tumors. The company utilizes proprietary gene engineering to enhance T-cell fitness and persistence against unique cancer-specific intracellular targets.
Biotech
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Similar biotechnology company
ImmuXell Biotechnology is a clinical-stage biopharmaceutical innovation company headquartered in Shanghai, China. Founded in 2021, the company focuses on developing novel immune cell therapies targeted at treating solid tumor cancers.
Similar biotechnology company
KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.
Similar biotechnology company
Tiankeya (also known as Beijing TCR Cure Biopharma Technology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in China, with operations in China and the United States. The company focuses on the innovation, development, and clinical translation of engineered T cell and immune cell therapies to treat cancer and solid tumors.
Similar biotechnology company
Guangzhou Bio-gene Technology Co., Ltd. is a biotechnology company that develops chimeric antigen receptor T-cell (CAR-T) therapies and related products. It serves patients with hematological malignancies, solid tumors, and autoimmune diseases by providing innovative cellular immunotherapy solutions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Immugenia and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Immugeniaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →